Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study

Table 2

Statistical analysis of the mean differences in eGFR (mL/min/1.73 m²) at each assessment time points, including baseline, and at 3, 6, 9, 12, 15, and 18 months after initiating SGLT2i.

Mean difference in eGFR	3 month ( value)	6 month ( value)	9 month ( value)	12 month ( value)	15 month ( value)	18 month ( value)
Baseline	−1.76 (0.006)	−1.66 (0.014)	−1.81 (0.008)	−1.12 (0.103)	−3.12 (0.004)	−4.15 (0.001)
3 month		−1.64 (0.105)	0.53 (0.663)	−2.09 (0.135)	0.01 (0.722)	−0.15 (0.689)
6 month			0.91 (0.885)	0.10 (0.894)	−0.95 (0.565)	−1.75 (0.196)
9 month				−0.62 (0.553)	−1.24 (0.281)	0.50 (0.925)
12 month					−0.61 (0.712)	−4.54 (0.025)
15 month						−1.89 (0.152)

Statistically significant difference at .